GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ligand Pharmaceuticals Inc (STU:LGDN) » Definitions » Short Percentage of Float

Ligand Pharmaceuticals (STU:LGDN) Short Percentage of Float


View and export this data going back to 2013. Start your Free Trial

What is Ligand Pharmaceuticals Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Ligand Pharmaceuticals's Short Percentage of Float

For the Biotechnology subindustry, Ligand Pharmaceuticals's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ligand Pharmaceuticals's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Ligand Pharmaceuticals's Short Percentage of Float falls into.


Ligand Pharmaceuticals (STU:LGDN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ligand Pharmaceuticals Inc (STU:LGDN) » Definitions » Short Percentage of Float
Comparable Companies
MORF ARDX SLNO EWTX KURA RCUS NMRA DNA XNCR MRVI OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
LGND:USA
Address
3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA, USA, 92121
Website
https://www.ligand.com
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Ligand Pharmaceuticals (STU:LGDN) Headlines

No Headlines